A Phase 2A Multicenter Open-label Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants with Refractory Focal Epilepsy

Go Back to All Clinical Trials

A Phase 2A Multicenter Open-label Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants with Refractory Focal Epilepsy

Brief description of study

This is a clinical research study for an investigational drug called RAP-219 (the “study drug”) in patients with refractory focal epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with refractory focal epilepsy at the dose being studied. This study drug has already been tested in people.

Clinical Study Identifier: s24-00317

ClinicalTrials.gov Identifier: NCT06377930

Principal Investigator: Daniel Friedman.

Other Investigators: Mariana Figuera Losada, Jacqueline A French, Claude Steriade, Sarah Levy.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies